Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN63,9463,981,67
Msft-0,61
Nokia3,55453,7095-1,18
IBM-0,09
Mercedes-Benz Group AG60,1760,190,84
PFE-1,43
17.08.2024 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.08.2024 15:30:02
Takeda Pharm (TKPHF.PK, US Other OTC (Pink Sheets))
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
27,97 -5,81 26,90 2 010
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiTakeda Pharmaceutical Co Ltd
Ticker4502
Kmenové akcie:Ordinary Shares
RIC4502.T
ISINJP3463000004
Poslední známé roční výsledky31.03.2024
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.03.2024 49 281
Akcie v oběhu k 08.07.20241 577 532 609
MěnaJPY
Kontaktní informace
Ulice4F, 2-1-1, Nihombashihon-cho
MěstoCHUO-KU
PSČ103-8668
ZeměJapan
Kontatní osobaTokumasa Takeda
Funkce kontaktní osobyGlobal Finance Chief Accounting Officer & Corporate Controller
Telefon81 332 782 111
Fax81332782000
Kontatní telefon810 332 782 111

Business Summary: Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Financial Summary: BRIEF: For the three months ended 30 June 2024, Takeda Pharmaceutical Co Ltd revenues increased 14% to Y1.208T. Net income applicable to common stockholders increased 7% to Y95.25B. Revenues reflect United States segment increase of 15% to Y636.7B, Europe And Canada (Country) segment increase of 20% to Y269.8B. Net income was partially offset by Other operating expenses increase of 95% to Y64.25B (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Owners and Lessors of Other Non-Financial Assets
SICPharmaceutical Preparations
SICDiagnostic Substances
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Representative DirectorChristophe Weber5701.04.201527.06.2014
Chief Financial Officer, DirectorMilano Furuta5626.06.202401.04.2024
President of Research & Development, DirectorAndrew Plump58